FDA.reportPublic FDA data

VON WILLEBRAND FACTOR HUMAN Pharmacologic Class Indexing

Class set ID
c2a3eccb-9c03-49d8-9fa8-32b2623a10f4
Version
2
Effective date
20180813
Type
Indexing - Pharmacologic Class

Mapped DailyMed Labels#

Label, Manufacturer, Effective table
LabelManufacturerEffectiveSPL version
These highlights do not include all the information needed to use VONVENDI ® safely and effectively. See full prescribing information for VONVENDI. VONVENDI [von Willebrand factor (recombinant)] lyophilized powder for solution, for intravenous injection Initial U.S. Approval: 2015Takeda Pharmaceuticals America, Inc. | Baxalta US Inc. | Siegfried Hameln GmbH | Baxalta Manufacturing Sàrl2025102420
These highlights do not include all the information needed to use WILATE safely and effectively. See full prescribing information for WILATE. WILATE, von Willebrand Factor/Coagulation Factor VIII Complex (Human) Lyophilized Powder for Solution for Intravenous Injection Initial U.S. Approval: 2009 ----------------------------RECENT MAJOR CHANGES------------------- Indication and Usage (1) 12/2023 Dosage and Administration (2.2, 2.3) 11/2024Octapharma USA Inc2024111923
These highlights do not include all the information needed to use Wilate safely and effectively. See full prescribing information for Wilate. Wilate, von Willebrand Factor/Coagulation Factor VIII Complex (Human), Powder for Solution, for Intravenous Use Only. Initial U.S. Approval: 2009Octapharma Pharmazeutika Produktionsgesellschaft m.b.H.2010082012